34 results about "Cutaneous wound" patented technology

The present invention relates to a monolithic biomaterial. The monolithic biomaterial has a primary network of convective flow, microfluidic channels that are embedded in a substrate, where the substrate is diffusively permeable to aqueous solutes. The present invention also relates to a method of making the monolithic biomaterial, as well as methods of using the monolithic biomaterial to facilitate healing of a cutaneous wound of a mammalian subject and of regulating cells.

A topical composition for treating a cutaneous wound includes whole colostrum or one or more growth factors, as well as a base by which the whole colostrum or one or more growth factors are carried. The topical composition may also include, without limitation, immunomodulators, lactoferrin, enzymes, vitamins, minerals, amino acids, or combinations thereof. Other components may also be included in the topical composition, including, but not limited to, antiseptics, antimicrobial agents, and anesthetics. When applied to a wound, the bioactive topical composition promotes healing of the treated wound.

The present invention provides methods of reducing cutaneous scar formation by treating a cutaneous wound with a composition comprising a therapeutic agent that is a sodium channel blocker and / or an inhibitor of the Nax / SCN7A pathway. The present invention also provides wound cover components impregnated with such compositions, kits composed of such compositions with a wound dressing or sterile wipe, and mixtures of such compositions with a topical component (e.g., cream, ointment, or gel) suitable for application to a cutaneous wound. The present invention also provides compositions, kits, devices, and methods for treating skin conditions (e.g., dermatitis, psoriasis, or other skin conditions) with such compositions and devices. Examples of such therapeutic agents include, but are not limited to, an inhibitor of a gene or protein selected from: ENac, COX-2, PGE2, PI3K, PKB, Nax Prss8, IL-1β, IL-8, SAPK, Erk gene, p38 gene, PAR2, S100A8, S100A9, S100A12.

The present invention relates to a monolithic biomaterial. The monolithic biomaterial has a primary network of convective flow, microfluidic channels that are embedded in a substrate, where the substrate is diffusively permeable to aqueous solutes. The present invention also relates to a method of making the monolithic biomaterial, as well as methods of using the monolithic biomaterial to facilitate healing of a cutaneous wound of a mammalian subject and of regulating cells.

Disclosed are methods of polarizing macrophages to exhibit M2 phenotype, including introducing an effective amount of gingiva-derived mesenchymal stem cells to an environment comprising a population of macrophages such that the macrophages are in fluid communication with the gingiva-derived mesenchymal stem cells. Also disclosed are methods of promoting cutaneous wound healing including administering to a patient an effective amount of human gingiva-derived mesenchymal stem cells, thereby resulting in at least one of accelerated wound closure, rapid re-epithelialization, improved angiogenesis and improved tissue remodeling relative to untreated controls. Also disclosed are methods for attenuating contact hypersensitivity in a patient, the methods including administering to a patient an effective amount of human gingiva-derived mesenchymal stem cells at a time at least timeframe selected from the group consisting of before sensitization, after sensitization and before challenge and after challenge, thereby attenuating contact hypersensitity.

The present invention provides compositions and methods that promote wound healing in a subject with a cutaneous injury. In particular, the present invention provides systemic and / or local administration of one or more compositions that cause ganglioside depletion (e.g., glucosylceramide synthase (GCS) inhibitors) for the treatment of cutaneous wounds.

A method for restructuring a biological tissue comprising collagen fibrils selected from a venous tissue, a cardiac valvular tissue, a cutaneous or subcutaneous tissue, a tissue of a muscular tendon, a tissue of a muscular fascia or a tissue of a muscular aponeurosis, comprising the following operational steps: a) bringing into contact a biological tissue comprising collagen fibrils with a cross-linking chemical composition able to induce cross-linking of collagen fibrils consequent to activation through electromagnetic radiation; b) activating said cross linking chemical composition through exposure to an electromagnetic radiation; c) cross-linking the collagen fibrils of said biological tissue in order to obtain a restructured biological tissue. The method according to the invention can be applied to recover a venous continence and both a venous and a cardiac valve diameter. The method reduces the visibility of cutaneous wrinkles, reinforces or repairs tendons, muscular fascia and aponeurosis as well as to heals surgical or traumatic cutaneous wounds or cutaneous ulcers.

The present invention relates to use of Bcl inhibitors for the prevention of fibroproliferation resulting in the growth of visible or disfiguring scar tissue on human skin, including without limitation keloids and hypertrophic scars. In particular, the present invention relates to the new use of small molecule inhibitors of the Bcl-2 / Bcl-XL family of anti-apoptotic proteins for the treatment of cutaneous wounds, burns and abrasions during the healing phase.

The present invention provides compositions and methods useful in the treatment of wounds, particularly in reducing or preventing scar formation, particularly hypertrophic scar or keloid formation. The invention thus further provides methods of treatment, including methods useful in hypertrophic scar or keloid revision as well as prophylactic, scar inhibiting methods.

Disclosed are methods of treating a subject suffering from a cutaneous wound comprising administering to the subject a CIRP inhibitor.

The present invention provides a method for treating wounds by applying cells as described in this application. In one aspect the method provides treatment for cutaneous wounds. In general embodiments the cells are delivered to the wound without being attached to a functionalized substrate in the delivery vehicle.

The present invention provides a topical composition comprising (i) an amount of an AP-1 signaling inhibitor sufficient to reduce, delay or prevent apoptosis and / or necrosis induced by dermal wounding and / or to induce and / or enhance proliferation of a cell; and (ii) a suitable carrier or excipient e.g., a topical carrier or excipient or other carrier or excipient for dermal application. For example, the AP-1 signaling inhibitor is a peptide analog comprising the sequence set forth in SEQ ID NO: 104. The present invention also provides a method of treating a dermal wound comprising topically administering said topical composition to a subject suffering from a dermal wound.

Compositions and methods are provided for enhanced healing of wounds, e.g. cutaneous wounds, by application of a scaffold or matrix, e.g. a hydrogel film comprising a dose of macrophages, or monocyte progenitors thereof, which dose is effective in increasing the rate of wound healing. The compositions of the invention find use in treating cutaneous wounds, particularly chronic wounds, e.g. in diabetic patients or other patients with impaired wound healing.

The present invention concerns the use of cells derived from the cellular fraction of the vascular stroma of the extramedullary adipose tissue to promote the regeneration of tissue following lesions caused by irradiation. More specifically, the use according to the invention aims to prepare a drug for promoting regeneration of the skin, and in particular to repair the cutaneous wounds caused by irradiation.

A method for restructuring a biological tissue comprising collagen fibrils selected from a venous tissue, a cardiac valvular tissue, a cutaneous or subcutaneous tissue, a tissue of a muscular tendon, a tissue of a muscular fascia or a tissue of a muscular aponeurosis, comprising the following operational steps: a) bringing into contact a biological tissue comprising collagen fibrils with a cross-linking chemical composition able to induce cross-linking of collagen fibrils consequent to activation through electromagnetic radiation; b) activating said cross linking chemical composition through exposure to an electromagnetic radiation; c) cross-linking the collagen fibrils of said biological tissue in order to obtain a restructured biological tissue. The method according to the invention can be applied to recover a venous continence and both a venous and a cardiac valve diameter. The method reduces the visibility of cutaneous wrinkles, reinforces or repairs tendons, muscular fascia and aponeurosis as well as to heals surgical or traumatic cutaneous wounds or cutaneous ulcers.

The present application relates to treatment of cutaneous wounds using IL-12. The methods of the invention result in improved wound closure. The methods comprise treating cutaneous wounds using topical, subcutaneous, and / or intramuscular administration of IL-12.

Disclosed is a method of promoting wound healing or wound closure. The method comprises administration of a miR-198 inhibitor and / or a follistatin-like-1 (FSTL1) polypeptide. Also disclosed are method of treating chronic cutaneous wounds, method of identifying a non-healing wound, use and a pharmaceutical composition comprising a miR-198 inhibitor and / or a follistatin-like-1 (FSTL1) polypeptide.

Disclosed are methods of polarizing macrophages to exhibit M2 phenotype, including introducing an effective amount of gingiva-derived mesenchymal stem cells to an environment comprising a population of macrophages such that the macrophages are in fluid communication with the gingiva-derived mesenchymal stem cells. Also disclosed are methods of promoting cutaneous wound healing including administering to a patient an effective amount of human gingiva-derived mesenchymal stem cells, thereby resulting in at least one of accelerated wound closure, rapid re-epithelialization, improved angiogenesis and improved tissue remodeling relative to untreated controls. Also disclosed are methods for attenuating contact hypersensitivity in a patient, the methods including administering to a patient an effective amount of human gingiva-derived mesenchymal stem cells at a time at least timeframe selected from the group consisting of before sensitization, after sensitization and before challenge and after challenge, thereby attenuating contact hypersensitivity.

The present invention provides a method for treating wounds by applying cells as described in this application. In one aspect the method provides treatment for cutaneous wounds. In general embodiments the cells are delivered to the wound without being attached to a functionalized substrate in the delivery vehicle.

The present invention relates to methods of inhibiting scar formation in a skin wound as well as methods of promoting tissue regeneration in a skin wound in a subject in need thereof comprising administering in or near said wound an effective amount of one or more neurotoxins.

The object of the present invention is a composition in powder form comprising the following polysaccharides alginic acid or sodium alginate,—pectin, chitosan, wherein the % by weight of the polysaccharides is at least 20% with respect to the total weight of the powder. The process for preparing said powder by an atomization process and its use in the treatment of cutaneous wounds and in the sector of food preservation are additional objects of the invention. Moreover, additional objects of the invention are the composition in the form of solution or liquid suspension that represents the starting material to obtain said powder and the process for preparing said liquid composition.

Cutaneous ulcers and non-healing skin wounds are a route for infection and represent a source of significant morbidity and mortality for humans. The present disclosure provides methods and compositions for treating, healing or preventing cutaneous ulcers and non-healing cutaneous wounds via the topical application of an effective amount of a nitric oxide (NO)-donating prostaglandin F2-alpha (PGF2-alpha) analog directly to the affected ulcer or non-healing cutaneous wound of a human in need of such treatment

The present invention provides methods of reducing cutaneous scar formation by treating a cutaneous wound with a composition comprising a therapeutic agent that is a sodium channel blocker and / or an inhibitor of the Nax / SCN7A pathway. The present invention also provides wound cover components impregnated with such compositions, kits composed of such compositions with a wound dressing or sterile wipe, and mixtures of such compositions with a topical component (e.g., cream, ointment, or gel) suitable for application to a cutaneous wound. The present invention also provides compositions, kits, devices, and methods for treating skin conditions (e.g., dermatitis, psoriasis, or other skin conditions) with such compositions and devices. Examples of such therapeutic agents include, but are not limited to, an inhibitor of a gene or protein selected from: ENac, COX-2, PGE2, PI3K, PKB, Nax Prss8, IL-1β, IL-8, SAPK, Erk gene, p38 gene, PAR2, S100A8, S100A9, S100A12.

The present invention provides compositions and methods that promote wound healing in a subject with a cutaneous injury. In particular, the present invention provides systemic and / or local administration of one or more compositions that cause ganglioside depletion (e.g., glucosylceramide synthase (GCS) inhibitors) for the treatment of cutaneous wounds.

The invention relates to a field of tissue repair and regeneration. More particularly, the invention relates to a composition for promoting cutaneous wound healing. In one embodiment, the composition is composed of one or more metazoan parasites or a mimic thereof sufficient to promote helminth-induced type-2 immune response. Preferably, the composition contains N. brasiliensis excretory / secretory antigen (NES) or an immune triggering portion thereof. The invention also relates to a method of accelerating wound healing in a subject in need of such treatment.

The object of the present invention is a composition in powder form comprising the following polysaccharides alginic acid or sodium alginate, - pectin, chitosan, wherein the % by weight of the polysaccharides is at least 20% with respect to the total weight of the powder. The process for preparing said powder by an atomization process and its use in the treatment of cutaneous wounds and in the sector of food preservation are additional objects of the invention. Moreover, additional objects of the invention are the composition in the form of solution or liquid suspension that represents the starting material to obtain said powder and the process for preparing said liquid composition.

The present invention provides compositions and methods to enhance cutaneous wound healing in subjects afflicted with, or at risk for, a pulmonary infection and / or a pulmonary injury. More specifically, the embodiments of the present invention relate to using fibrin carrier as a vehicle to topically deliver one or more chemokine onto a cutaneous wound so as to accelerate wound healing.

The present invention relates to topical compositions containing extracts of the plant genus Stryphnodendron as well as their preparation and application. The compositions contain between 1% and 6% of total phenols and are useful for the treatment of cutaneous wounds.

The present invention concerns the use of cells derived from the cellular fraction of the vascular stroma of the extramedullary adipose tissue to promote the regeneration of tissue following lesions caused by irradiation. More specifically, the use according to the invention aims to prepare a drug for promoting regeneration of the skin, and in particular to repair the cutaneous wounds caused by irradiation.